27 related articles for article (PubMed ID: 16673595)
1. Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients.
Lo EN; Beckett LA; Pan CX; Robles D; Suga JM; Sands JM; Lara PN
Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):144-8. PubMed ID: 25667107
[TBL] [Abstract][Full Text] [Related]
2. Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review.
Tresnanda RI; Pramod SV; Safriadi F
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3101-3107. PubMed ID: 34710984
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer.
Wilkinson S; Chodak G
Eur Urol; 2004 May; 45(5):581-4; discussion 585. PubMed ID: 15082199
[TBL] [Abstract][Full Text] [Related]
4. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.
Small EJ; Baron A; Bok R
Cancer; 1997 Nov; 80(9):1755-9. PubMed ID: 9351544
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore.
Ngo LS; Yeo A; Wong AS; Tay MH
Ann Acad Med Singap; 2007 Oct; 36(10):811-4. PubMed ID: 17987231
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.
Ellerhorst JA; Tu SM; Amato RJ; Finn L; Millikan RE; Pagliaro LC; Jackson A; Logothetis CJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2371-6. PubMed ID: 9815636
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of high-doses ketoconazole with hydrocortisone substitution in hormone-refractory prostate cancer.
Argirovic Dj
Acta Chir Iugosl; 2005; 52(4):51-4. PubMed ID: 16673595
[TBL] [Abstract][Full Text] [Related]
9. [Treatment options for hormone-refractory prostate cancer].
Heidenreich A; Ohlmann CH
Urologe A; 2005 Nov; 44(11):1303-4, 1306-14. PubMed ID: 16237541
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer.
Loberg RD; Fielhauer JR; Pienta BA; Dresden S; Christmas P; Kalikin LM; Olson KB; Pienta KJ
Urology; 2003 Dec; 62 Suppl 1():128-33. PubMed ID: 14747050
[TBL] [Abstract][Full Text] [Related]
11. Hormone refractory disease.
Mahler C; Denis LJ
Semin Surg Oncol; 1995; 11(1):77-83. PubMed ID: 7538695
[TBL] [Abstract][Full Text] [Related]
12. Ketoconazole and liarozole in the treatment of advanced prostatic cancer.
Mahler C; Verhelst J; Denis L
Cancer; 1993 Feb; 71(3 Suppl):1068-73. PubMed ID: 8428329
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
